CA2985819A1 - Bacteria engineered to reduce hyperphenylalaninemia - Google Patents

Bacteria engineered to reduce hyperphenylalaninemia Download PDF

Info

Publication number
CA2985819A1
CA2985819A1 CA2985819A CA2985819A CA2985819A1 CA 2985819 A1 CA2985819 A1 CA 2985819A1 CA 2985819 A CA2985819 A CA 2985819A CA 2985819 A CA2985819 A CA 2985819A CA 2985819 A1 CA2985819 A1 CA 2985819A1
Authority
CA
Canada
Prior art keywords
gene
promoter
genetically engineered
phenylalanine
pal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2985819A
Other languages
English (en)
French (fr)
Inventor
Dean Falb
Vincent M. Isabella
Jonathan W. Kotula
Paul F. Miller
Sarah ROWE
Yves Millet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synlogic Operating Co Inc
Original Assignee
Synlogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synlogic Inc filed Critical Synlogic Inc
Publication of CA2985819A1 publication Critical patent/CA2985819A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03002—L-Amino-acid oxidase (1.4.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y403/00—Carbon-nitrogen lyases (4.3)
    • C12Y403/01—Ammonia-lyases (4.3.1)
    • C12Y403/01024—Phenylalanine ammonia-lyase (4.3.1.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2985819A 2015-05-13 2016-05-13 Bacteria engineered to reduce hyperphenylalaninemia Pending CA2985819A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562161137P 2015-05-13 2015-05-13
US62/161,137 2015-05-13
US201562256052P 2015-11-16 2015-11-16
US62/256,052 2015-11-16
PCT/US2016/032562 WO2016183531A1 (en) 2015-05-13 2016-05-13 Bacteria engineered to reduce hyperphenylalaninemia

Publications (1)

Publication Number Publication Date
CA2985819A1 true CA2985819A1 (en) 2016-11-17

Family

ID=56117975

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2985819A Pending CA2985819A1 (en) 2015-05-13 2016-05-13 Bacteria engineered to reduce hyperphenylalaninemia

Country Status (12)

Country Link
US (6) US10610546B2 (https=)
EP (2) EP3882259B1 (https=)
JP (3) JP6843768B2 (https=)
AU (3) AU2016262569B9 (https=)
BR (1) BR112017024384A2 (https=)
CA (1) CA2985819A1 (https=)
ES (1) ES2881384T3 (https=)
IL (2) IL296538A (https=)
PL (1) PL3294760T3 (https=)
SG (1) SG10202003100XA (https=)
WO (1) WO2016183531A1 (https=)
ZA (1) ZA201707678B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112662606A (zh) * 2021-01-06 2021-04-16 中国科学院分子植物科学卓越创新中心 用于治疗苯丙酮尿症的工程益生菌

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2865825T3 (es) 2014-04-01 2021-10-18 Rubius Therapeutics Inc Procedimientos y composiciones para inmunomodulación
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
US10610546B2 (en) 2015-05-13 2020-04-07 Synlogic Operating Company Inc. Bacteria engineered to reduce hyperphenylalaninemia
US20160206666A1 (en) 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
CN107667173A (zh) 2015-05-06 2018-02-06 斯尼普技术有限公司 改变微生物种群和改善微生物群
US11883439B2 (en) 2015-05-13 2024-01-30 Synlogic Operating Company, Inc. Bacteria engineered to treat a disease or disorder
EP3294757B1 (en) * 2015-05-13 2023-12-27 Synlogic Operating Company, Inc. Bacteria engineered to treat a disease or disorder
US11685925B2 (en) 2015-10-30 2023-06-27 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
WO2017087580A1 (en) * 2015-11-16 2017-05-26 Synlogic, Inc. Bacteria engineered to reduce hyperphenylalaninemia
US11208649B2 (en) 2015-12-07 2021-12-28 Zymergen Inc. HTP genomic engineering platform
US9988624B2 (en) 2015-12-07 2018-06-05 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
WO2018112194A1 (en) 2016-12-15 2018-06-21 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
WO2018183685A1 (en) * 2017-03-29 2018-10-04 President And Fellows Of Harvard College Methods of regulating gene expression in a cell
WO2018191715A2 (en) * 2017-04-14 2018-10-18 Synthetic Genomics, Inc. Polypeptides with type v crispr activity and uses thereof
CN111655841A (zh) 2017-06-21 2020-09-11 同生运营公司 用于治疗紊乱的细菌
EP3679142A4 (en) 2017-09-08 2021-04-28 New Portal Limited NUCLEIC ACID SYSTEMS FOR THE TARGETED DIRECTION OF BACTERIA AGAINST SOLID TUMORS VIA GLUCOSE-DEPENDENT VIVILABILITY
US10849938B2 (en) 2017-09-13 2020-12-01 ZBiotics Company Gene expression system for probiotic microorganisms
CN107904222B (zh) * 2017-11-30 2019-10-08 江南大学 一种热稳定性提高的l-氨基酸脱氨酶突变体及其构建方法
JP7460531B2 (ja) 2017-12-05 2024-04-02 バイオピーエルエックス，インコーポレイティド 微生物感染を防ぐための方法および組成物
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
JP2022512380A (ja) 2018-12-10 2022-02-03 ノヴォム バイオテクノロジーズ，インコーポレイテッド 高シュウ酸尿症を治療するための方法及び組成物
WO2020132017A1 (en) * 2018-12-20 2020-06-25 University Of South Carolina Pharmabiotic treatments for metabolic disorders
WO2020223345A1 (en) 2019-04-29 2020-11-05 Antipov Eugene Enumeration of genetically engineered microorganisms by live cell counting techniques
AU2020288624B2 (en) 2019-06-04 2025-09-25 Cocoon Biotech Inc. Silk-based products, formulations, and methods of use
CN114450403A (zh) * 2019-06-21 2022-05-06 银杏生物制品公司 用于在枫糖尿症(msud)的治疗中使用的酶的生物合成
CN110257291B (zh) * 2019-06-25 2021-07-23 北京大学 一株耐受镍离子毒性的无色杆菌及其应用
CA3156035A1 (en) 2019-09-27 2021-04-01 Intrexon Actobiotics Nv D/B/A Precigen Actobio Treatment of celiac disease
CA3161450A1 (en) 2019-11-12 2021-05-20 Actym Therapeutics, Inc. Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
AU2021208600A1 (en) 2020-01-17 2022-07-28 Université Catholique de Louvain Genetically modified bacterium with altered envelop integrity and uses thereof
US20230105474A1 (en) * 2020-02-25 2023-04-06 Synlogic Operating Company, Inc. Recombinant bacteria engineered to treat diseases associated with uric acid and methods of use thereof
CN115298308A (zh) * 2020-03-20 2022-11-04 同生运营公司 经工程化以减轻高苯丙氨酸血症的微生物
WO2021207647A1 (en) * 2020-04-09 2021-10-14 Computational International LLC Small molecule drugs as targeted therapeutics
CA3188581A1 (en) * 2020-07-02 2022-01-06 The Regents Of The University Of California Persistent memory t-cell responses to cancer and infectious-disease antigens by manipulation of amino acid-catabolism pathways
WO2022006748A1 (en) 2020-07-07 2022-01-13 New Portal Limited Genetically engineered live bacteria and methods of constructing the same
WO2022036159A2 (en) 2020-08-12 2022-02-17 Actym Therapeutics, Inc. Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
US20230332164A1 (en) * 2020-09-30 2023-10-19 Synlogic Operating Company, Inc. Bacteria engineered to secrete active proteins
US20230414732A1 (en) * 2020-11-10 2023-12-28 Palena Therapeutics, Inc. Compositions of embedded epitope random peptides (eerp) for treatment of immune-mediated conditions, and methods of use
WO2022120028A2 (en) 2020-12-02 2022-06-09 Synlogic Operating Company, Inc. Engineered microorganisms
CN112501098B (zh) * 2020-12-11 2023-01-03 上海陶宇晟生物技术有限责任公司 具有降解苯丙氨酸能力的工程益生菌
US20240316121A1 (en) 2020-12-31 2024-09-26 Synlogic Operating Company, Inc. Microorganisms engineered to reduce hyperphenylalaninemia
CN112662607A (zh) * 2021-01-07 2021-04-16 上海陶宇晟生物技术有限责任公司 具备表面展示苯丙氨酸解氨酶的工程益生菌
CN117479929A (zh) * 2021-06-24 2024-01-30 龙沙格林伍德有限公司 控制活性物质向消化道施用的方法
CA3235418A1 (en) 2021-11-09 2023-05-19 Actym Therapeutics, Inc. Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
CN116836899A (zh) * 2022-03-02 2023-10-03 和度生物技术(上海)有限公司 一种用于治疗高苯丙氨酸血症的工程微生物及其用途
CN114717172B (zh) * 2022-03-21 2022-09-23 江南大学 合成l-缬氨酸的大肠杆菌及其构建方法与应用
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
CN116463362B (zh) * 2023-06-15 2023-09-19 中国中医科学院中药研究所 一种细胞分裂抑制剂的制备方法
WO2025170927A1 (en) * 2024-02-06 2025-08-14 The Cleveland Clinic Foundation Kynurenine responsive bacteria and cancer therapies

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
CN1154845A (zh) 1996-09-09 1997-07-23 首都医学院附属北京红十字朝阳医院 能表达活性苯丙氨酸脱氨酶的基因工程菌口服制剂
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
EP1135461A4 (en) 1998-12-02 2003-03-26 Univ Boston GEN NETWORKS FOR CONTROLLING GENE EXPRESSION
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
JP4682454B2 (ja) 2000-06-28 2011-05-11 味の素株式会社 新規変異型ｎ−アセチルグルタミン酸合成酵素及びｌ−アルギニンの製造法
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
WO2002090551A2 (en) 2001-05-03 2002-11-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Self-containing lactococcus strain
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
JP4452914B2 (ja) 2003-09-08 2010-04-21 味の素株式会社 新規トランスポータタンパク質
AU2005321630A1 (en) 2004-07-02 2006-07-06 Metanomics Gmbh Process for the production of fine chemicals
US7553653B2 (en) 2004-09-17 2009-06-30 Biomarin Pharmaceutical Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
ZA200704766B (en) 2004-11-30 2008-09-25 Aeras Global Tb Vaccine Found Bacterial packaging strains useful for generation and production of recombinant double-stranded RNA nucleocapsids and uses thereof
GB0501540D0 (en) 2005-01-25 2005-03-02 Univ Leeds Controlled production and delivery of biologically active agents by gut bacteria
EP2886658A1 (en) 2005-03-10 2015-06-24 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
EP2029739A4 (en) 2006-06-02 2009-11-25 Verenium Corp LYASE ENZYMES, NUCLEIC ACIDS FOR THEIR CODING AND METHOD FOR THEIR PREPARATION AND USE
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
US9084434B2 (en) 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
US20100297249A1 (en) 2007-07-05 2010-11-25 North-West University Enhancement of the efficacy of therapeutic proteins
CN101586111B (zh) * 2008-05-22 2012-03-07 北京三元基因工程有限公司 一种活性乳酸乳球菌制品的制备方法
DK3181682T3 (da) 2008-09-29 2021-07-05 Intrexon Actobiotics Nv Reduceret kolonisering af mikrober på slimhinden
WO2011015985A2 (en) 2009-08-04 2011-02-10 Evogene Ltd. Polynucleotides and polypeptides for increasing desirable plant qualities
WO2011080505A2 (en) 2009-12-28 2011-07-07 Bigdna Ltd Method of growing phage for commercial use
RU2603061C2 (ru) 2010-03-02 2016-11-20 Ренессанс Байосайенс Корп., Функциональное улучшение микроорганизмов для минимизации продукции акриламида
US8129170B1 (en) 2010-12-06 2012-03-06 E.I. Du Pont De Nemours And Company Recombinant bacteria having the ability to metabolize sucrose
US9409950B2 (en) 2010-12-23 2016-08-09 Biogen Ma Inc. Linker peptides and polypeptides comprising same
US9017961B2 (en) * 2012-03-05 2015-04-28 E.I. Du Pont De Nemours And Company Recombinant bacteria comprising novel sucrose transporters
FR2990699B1 (fr) 2012-05-21 2016-02-05 Agronomique Inst Nat Rech Cassettes d'expression procaryotes regulees par le stress
DK2864491T3 (en) 2012-06-22 2018-12-17 Phytogene Inc Enzymes and methods for styrene synthesis
CA2880620A1 (en) 2012-07-27 2014-01-30 University Of North Texas Genetically modified probiotic for the treatment of phenylketonuria (pku) disease
US20150246085A1 (en) * 2012-11-01 2015-09-03 The Sydney Children's Hospital Network (Randwick & Westmead) Genetically-Modified Probiotic for Treatment of Phenylketonuria
JP6419082B2 (ja) 2012-12-13 2018-11-07 マサチューセッツ インスティテュート オブ テクノロジー リコンビナーゼに基づく論理／メモリシステム
EP2964240B1 (en) 2013-03-07 2018-10-24 The General Hospital Corporation Compositions and methods for bacterial delivery of polypeptides
KR102218930B1 (ko) 2013-04-18 2021-02-23 코덱시스, 인코포레이티드 조작된 페닐알라닌 암모니아 리아제 폴리펩티드
US10610546B2 (en) 2015-05-13 2020-04-07 Synlogic Operating Company Inc. Bacteria engineered to reduce hyperphenylalaninemia
SG11201704543XA (en) * 2014-12-05 2017-07-28 Synlogic Inc Bacteria engineered to treat diseases associated with hyperammonemia
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
EP3294757B1 (en) 2015-05-13 2023-12-27 Synlogic Operating Company, Inc. Bacteria engineered to treat a disease or disorder
CA2987508A1 (en) 2015-05-28 2016-12-01 Evolva Sa Biosynthesis of phenylpropanoids and phenylpropanoid derivatives
IL256216B (en) * 2015-06-10 2022-07-01 Synlogic Operating Co Inc Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
WO2016210373A2 (en) 2015-06-24 2016-12-29 Synlogic, Inc. Recombinant bacteria engineered for biosafety, pharmaceutical compositions, and methods of use thereof
US20170216370A1 (en) 2015-07-31 2017-08-03 Synlogic, Inc. Bacteria engineered to treat disorders involving propionate catabolism
WO2017087580A1 (en) 2015-11-16 2017-05-26 Synlogic, Inc. Bacteria engineered to reduce hyperphenylalaninemia
WO2017216704A1 (en) 2016-06-13 2017-12-21 Benson Hill Biosystems, Inc. Increasing plant growth and yield by using a phenylalanine ammonia lyase sequence
CN111655841A (zh) 2017-06-21 2020-09-11 同生运营公司 用于治疗紊乱的细菌
JP2021531749A (ja) 2018-07-12 2021-11-25 コデクシス， インコーポレイテッド 操作されたフェニルアラニンアンモニアリアーゼポリペプチド
CN115298308A (zh) 2020-03-20 2022-11-04 同生运营公司 经工程化以减轻高苯丙氨酸血症的微生物
US20240316121A1 (en) 2020-12-31 2024-09-26 Synlogic Operating Company, Inc. Microorganisms engineered to reduce hyperphenylalaninemia
WO2023044479A1 (en) 2021-09-17 2023-03-23 Synlogic Operating Company, Inc. Methods for reducing hyperphenylalaninemia

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112662606A (zh) * 2021-01-06 2021-04-16 中国科学院分子植物科学卓越创新中心 用于治疗苯丙酮尿症的工程益生菌

Also Published As

Publication number Publication date
IL255616A (en) 2018-01-31
AU2016262569A1 (en) 2018-01-04
US20180169154A1 (en) 2018-06-21
AU2016262569B2 (en) 2021-05-06
EP3294760B1 (en) 2021-03-24
EP3882259B1 (en) 2026-01-28
ES2881384T3 (es) 2021-11-29
US10610546B2 (en) 2020-04-07
AU2021212141B2 (en) 2024-09-19
US20170136073A1 (en) 2017-05-18
IL296538A (en) 2022-11-01
BR112017024384A2 (pt) 2018-07-24
EP3294760A1 (en) 2018-03-21
NZ737318A (en) 2025-03-28
PL3294760T3 (pl) 2021-11-08
NZ775981A (en) 2025-03-28
US20180280451A9 (en) 2018-10-04
ZA201707678B (en) 2021-03-31
AU2021212141A1 (en) 2021-08-26
US9889164B2 (en) 2018-02-13
US12409195B2 (en) 2025-09-09
JP2023085295A (ja) 2023-06-20
US9943555B2 (en) 2018-04-17
EP3882259A1 (en) 2021-09-22
AU2016262569B9 (en) 2021-09-16
WO2016183531A1 (en) 2016-11-17
JP7592777B2 (ja) 2024-12-02
US20160340665A1 (en) 2016-11-24
JP2021097685A (ja) 2021-07-01
US20200246394A1 (en) 2020-08-06
US10195234B2 (en) 2019-02-05
US10933102B2 (en) 2021-03-02
US20170312320A1 (en) 2017-11-02
JP7245271B2 (ja) 2023-03-23
JP2018515106A (ja) 2018-06-14
IL255616B (en) 2022-10-01
JP6843768B2 (ja) 2021-03-17
AU2024278562A1 (en) 2025-01-09
SG10202003100XA (en) 2020-05-28
US20170014457A1 (en) 2017-01-19
IL255616B2 (en) 2023-02-01

Similar Documents

Publication Publication Date Title
AU2021212141B2 (en) Bacteria engineered to reduce hyperphenylalaninemia
JP7494345B2 (ja) 高フェニルアラニン血症を低減させるように操作された細菌
EP3307870B1 (en) Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
JP2018535678A5 (https=)
CA3167394A1 (en) Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof
CA2996535A1 (en) Bacteria engineered to treat disorders involving propionate catabolism
US20220168362A1 (en) Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
HK40085223A (en) Bacteria engineered to reduce hyperphenylalaninemia
CA3005451C (en) Bacteria engineered to reduce hyperphenylalaninemia

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210512

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241024

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250120

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250204

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250204

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251010

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251010

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251103

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251209

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251216